The purpose of this study is to analyze the predictive performance of (TIMP-2)*(IGFBP7) for moderate and severe AKI in patients with SARS-CoV-2 associated ARDS within the first 7 days.


Study design

PredictAKI in COVID19 is an international multi-centre, prospective observational study.


Inclusion criteria

  1. Moderate or severe ARDS according to the Berlin definition (moderate: paO2/FiO2=101-200mmHg with PEEP≥5cmH2O, severe: paO2/FiO2≤100mmHg with PEEP≥5cmH2O)
  2. SARS-CoV2 positive test
  3. Age ≥ 18 years
  4. Informed consent


Exclusion criteria

  1. Pre-existing AKI
  2. Severe CKD with eGFR<20ml/min
  3. Chronic dialysis dependency
  4. Kidney transplant within the last 12 months
  5. Pregnancy, breastfeeding
  6. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.


For further information, please contact aki@anit.uni-muenster.de